Brief: Vistagen Receives Notice Of Allowance For Av-101 Canadian Patent For Treatment Of Dyskinesia Related To Levodopa Therapy For Parkinson’S Disease
13/07/2023 21:12
July 13 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN RECEIVES NOTICE OF ALLOWANCE FOR AV-101 CANADIAN
PATENT
FOR TREATMENT OF DYSKINESIA RELATED TO LEVODOPA THERAPY FOR
PARKINSON’S DISEASE
Source text for Eikon: ID:nBw7mLKQsa
Further company coverage: VTGN.O
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors